Figures & data
Figure 1. (A) Synthesis of PBLA-PEG-PBLA triblock copolymers. (B) 1H NMR spectrogram of PBLA-PEG-PBLA. (C) Phase diagrams of the PBLA-PEG-PBLA copolymer aqueous solutions.
![Figure 1. (A) Synthesis of PBLA-PEG-PBLA triblock copolymers. (B) 1H NMR spectrogram of PBLA-PEG-PBLA. (C) Phase diagrams of the PBLA-PEG-PBLA copolymer aqueous solutions.](/cms/asset/0c85dbf8-cf7c-448e-9fd9-790fea0b532e/idrd_a_1413448_f0001_b.jpg)
Figure 2. (A) Phase transition process of copolymer solutions (15%, w/w) characterized by the variance of storage modulus and loss modulus as a function of temperature. (B) Storage modulus of copolymer solutions at different concentration as a function of temperature. (C) Viscosity of copolymer solutions at different concentration as a function of temperature. (D) Required force to inject copolymer solution (15%, w/w) from 1 mL syringes equipped with 24 G × 20 mm, 27 G× 12.9 mm needles into air at the crosshead speed of 1 mm·s−1. (E) Required force to inject copolymer solutions at different concentration from 1 mL syringes equipped with 27 G × 12.9 mm needles into air at the crosshead speed of 1 mm·s−1. (F) Variation trend of gelation temperature and required force to inject copolymer solutions on different concentration of PBLA-PEG-PBLA solution.
![Figure 2. (A) Phase transition process of copolymer solutions (15%, w/w) characterized by the variance of storage modulus and loss modulus as a function of temperature. (B) Storage modulus of copolymer solutions at different concentration as a function of temperature. (C) Viscosity of copolymer solutions at different concentration as a function of temperature. (D) Required force to inject copolymer solution (15%, w/w) from 1 mL syringes equipped with 24 G × 20 mm, 27 G× 12.9 mm needles into air at the crosshead speed of 1 mm·s−1. (E) Required force to inject copolymer solutions at different concentration from 1 mL syringes equipped with 27 G × 12.9 mm needles into air at the crosshead speed of 1 mm·s−1. (F) Variation trend of gelation temperature and required force to inject copolymer solutions on different concentration of PBLA-PEG-PBLA solution.](/cms/asset/132b3d04-8c67-4024-9c9a-2184220b38b9/idrd_a_1413448_f0002_c.jpg)
Figure 3. (A) Percent of the remaining hydrogel during in vitro degradation in PBS at 37 °C. The concentrations of polymer were 10, 15, and 20% (w/w), respectively. (B) Morphology of PBLA-PEG-PBLA hydrogel with different polymer concentration 10, 15, and 20% (w/w). (C) GPC chromatograms of the remaining gels during in vitro degradation. (D) GPC chromatograms of the degraded hydrogels during in vitro degradation.
![Figure 3. (A) Percent of the remaining hydrogel during in vitro degradation in PBS at 37 °C. The concentrations of polymer were 10, 15, and 20% (w/w), respectively. (B) Morphology of PBLA-PEG-PBLA hydrogel with different polymer concentration 10, 15, and 20% (w/w). (C) GPC chromatograms of the remaining gels during in vitro degradation. (D) GPC chromatograms of the degraded hydrogels during in vitro degradation.](/cms/asset/7aae959e-796a-479b-b765-49f9980b7acc/idrd_a_1413448_f0003_c.jpg)
Figure 4. (A) Viscosity of GCV in situ hydrogel as a function of temperature. (B) Required force to inject GCV in situ hydrogel from 1 mL syringers equipped with 27 G × 12.9 mm needles into air at the crosshead speed of 1 mm·s−1. (C) In vitro GCV release profiles from GCV in situ hydrogel in phosphate buffer solution (PBS, pH 7.4) at 37 °C with 1% hyaluronic acid (HA, w/w).
![Figure 4. (A) Viscosity of GCV in situ hydrogel as a function of temperature. (B) Required force to inject GCV in situ hydrogel from 1 mL syringers equipped with 27 G × 12.9 mm needles into air at the crosshead speed of 1 mm·s−1. (C) In vitro GCV release profiles from GCV in situ hydrogel in phosphate buffer solution (PBS, pH 7.4) at 37 °C with 1% hyaluronic acid (HA, w/w).](/cms/asset/ad843528-516f-4464-a824-4860ff513425/idrd_a_1413448_f0004_b.jpg)
Figure 5. Viability of L-02 cell culture with different concentration of PBLA-PEG-PBLA (A) and compare with SDS at 24 h (B); (C) histology of conjunctivae and sclera 2 weeks after intravitreous injection. Sections were embedded in paraffin and stained with H & E; (D) aqueous humor and (E) vitreous concentration-time profile of GCV after intravitreous injection of GCV in situ hydrogel and GCV injection in rabbits, respectively, (n = 6).
![Figure 5. Viability of L-02 cell culture with different concentration of PBLA-PEG-PBLA (A) and compare with SDS at 24 h (B); (C) histology of conjunctivae and sclera 2 weeks after intravitreous injection. Sections were embedded in paraffin and stained with H & E; (D) aqueous humor and (E) vitreous concentration-time profile of GCV after intravitreous injection of GCV in situ hydrogel and GCV injection in rabbits, respectively, (n = 6).](/cms/asset/1778674b-f31e-420f-898f-b20ba76da717/idrd_a_1413448_f0005_c.jpg)
Table 1. Pharmacokinetics parameter of GCV in aqueous humor and vitreous.